

The logo for Nyrada inc, featuring the company name in white text on a red square background.

Nyrada
inc


Investor Presentation

October 2024

Improving Lives, Offering Hope

Authorised by Mr. John Moore, Non-Executive
Chair, on behalf of the Board.

ASX:NYR



Important Notice and Disclaimer



This presentation has been prepared by Nyrada Inc (“**NYR**” or “**Company**”). It should not be considered as an offer or invitation to subscribe for, or purchase any securities in NYR, or as an inducement to purchase any securities in NYR. No agreement to subscribe for securities in NYR will be entered into on the basis of this presentation or any information, opinions or conclusions expressed in the course of this presentation.

This presentation is not a prospectus, product disclosure document, or other offering document under Australian law or under the law of any other jurisdiction. In particular, this presentation may not be released to US wire services or distributed in the United States.

This presentation does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or to, or for the account or benefit of, US persons. The Company’s CDIs have not been, and will not be, registered under the US Securities Act or the securities laws of any state or other jurisdiction of the United States. The CDIs may not be offered, sold or otherwise transferred in the United States except in a transaction exempt from, or not subject to, the registration requirements of the US Securities Act of 1933 and the applicable securities laws of any state or other jurisdiction in the United States. No person in the United States may, directly or indirectly, participate in the Company’s Security Purchase Plan.

It has been prepared for information purposes only. This presentation contains general summary information and does not take into account the investment objectives, financial situation and particular needs of an individual investor. It is not a financial product advice, and the Company is not licensed to, and does not provide, financial advice.

This presentation may contain forward-looking statements which are identified by words such as ‘may’, ‘could’, ‘believes’, ‘estimates’, ‘targets’, ‘expects’, or ‘intends’ and other similar words that involve risks and uncertainties. These statements are based on an assessment of past and present economic and operating conditions, and on a number of assumptions regarding future events and actions that, as at the date of this presentation, are expected to take place.

Such forward-looking statements do not guarantee of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors many of which are beyond the control of the Company, its Directors and management.

Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, none of the Company, its Directors or officers can give, or gives, any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this document will actually occur or that the assumptions on which those statements are based are exhaustive or will prove to be correct beyond the date of its making.

Readers are cautioned not to place undue reliance on these forward-looking statements. Except to the extent required by law, the Company has no intention to update or revise forward-looking statements, or to publish prospective financial information in the future, regardless of whether new information, future events or any other factors affect the information contained in this presentation.

Readers should make their own independent assessment of the information and take their own independent professional advice in relation to the information and any proposed action to be taken on the basis of the information. To the maximum extent permitted by law, the Company and its professional advisors and their related bodies corporate, affiliates and each of their respective directors, officers, management, employees, advisers and agents and any other person involved in the preparation of this presentation disclaim all liability and responsibility (including without limitation and liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use of or reliance on anything contained in, or omitted from, this presentation. Neither the Company nor its advisors have any responsibility or obligation to update this presentation or inform the reader of any matter arising or coming to their notice after the date of this presentation document which may affect any matter referred to in the presentation.

About Nyrada

- › Drug discovery and development company specialising in rational design of novel small molecule therapeutics.

- › Nyrada's lead drug candidate NYR-BI03:
 - › demonstrated strong preclinical efficacy protecting the brain from secondary injury following stroke.
 - › demonstrated strong preclinical efficacy in protecting heart following acute myocardial ischemia-reperfusion injury.
 - › preclinical TBI efficacy study with Walter Reed Army Institute of Research and UNSW in progress.
 - › Phase Ia Clinical Trial to commence end CY2024.

- › Undertaking exploratory works for other indications and opportunities.

- › Commercially focused business model and expert team.

Company Snapshot

Company Structure

ASX:NYR Overview at 24 October 2024

CDIs on Issue (m)	182.2
Share Price (AU\$)	\$0.14
Market Capitalisation (AU\$m)	\$25.5
Options and Performance Rights (m)*	71.8

* Includes options approved but not issued and options to be considered at 12 Nov. 2024 Annual General Meeting

Leadership


Nyrada Leadership

Non-Executive Chair	Mr. John Moore
Chief Executive Officer	Mr. James Bonnar
Chief Science Officer	Dr. Benny Evison
Chief Financial Officer	Mr. Cameron Jones
Scientific Advisory Board Chair	Prof. Gary Housley

Share Register – 24 October 2024

Position	Holder Name	Holding	% IC
1	NOXOPHARM LIMITED	33,373,245	18.32%
2	ALTNIA HOLDINGS PTY LTD	9,921,725	5.45%
3	MR XIAOJIAN HUANG	6,589,473	3.62%
4	KYRIACO BARBER PTY LTD	5,800,000	3.18%
5	SUNSET CAPITAL MANAGEMENT PTY LTD	4,000,000	2.20%
6	MR XIAO LI	3,500,000	1.92%
7	MS ROCHELLE SEMAAN	3,004,684	1.65%
8	HIMSTEDT & CO PTY LTD	3,000,000	1.65%
9	COLIN HOUSELY & FRED A HOUSELY	1,863,725	1.02%
10	BNP PARIBAS NOMINEES PTY LTD	1,665,452	0.91%
	Total	72,718,304	39.91%
	Total issued capital - selected security class(es)	182,208,698	100.00%

Price Chart



Nyrada Offer (1)

- › Nyrada Inc. (ASX:NYR) proposes to raise up to AU\$4.36 million (before costs) in new equity capital to fund new and existing growth opportunities.
- › Details of Placement:
 - › 28,000,000 CDIs through placement to sophisticated and institutional investors
 - › Placement under existing ASX LR 7.1 and 7.1A capacity.
 - › Issue Price of AU\$0.12 per CDI
- › Details of Securities Purchase Plan (SPP):
 - › 8,333,333 CDIs through SPP to eligible CDI holders
 - › Issue Price of AU\$0.12 per CDI
- › Details of Director Participation:
 - › 583,332 CDIs through placement to Nyrada Directors
 - › Issue Price of AU\$0.12 per CDI
 - › Subject to CDI holder approval at February 2025 EGM



Nyrada Offer (2)

- › Use of Funds
 - › Completion of Phase Ia clinical trial for NYR-BI03
 - › Preparation and submission of Investigational New Drug (IND) applications with the US Food and Drug Administration (FDA)
 - › Further research and development of NYR-BI03 in cardiac heart disease and other potential indications.
 - › Working capital and raise costs.



Investment Proposition

- › Pioneering transient receptor potential canonical (TRPC) channel blocking therapies.

- › Commencing first-in-human Phase Ia clinical trial in late 2024.

- › First-in-class neuroprotection and cardioprotection therapy with novel mode of action.

- › One drug asset targeting two significant therapeutic areas and three large markets.

- › Collaborations with world leading institutions: Walter Reed Army Institute of Research (WRAIR) and UNSW Sydney. Strategic partnership with Rebio.

- › Proven and globally experienced board and team.

- › Cash position of AU\$2.98M at 30 September 2024. AU\$1.38M R&D rebate expected around December 2024.

Nyrada's Lead Drug Candidate **NYR-BI03**



First-in-Class with Novel Mechanism of Action

- › NYR-BI03 is a first-in-class therapy.
- › Novel mechanism of action.
- › Australian developed innovation.
- › Entering clinic in late CY2024.



Significant Unmet Clinical Need and Market Opportunity

- › Targeting multiple indications.
- › Stroke, TBI and ischemia-Reperfusion injury are leading causes of death and disability.
- › No current FDA approved drugs to treat these conditions.

One Drug

►► **NYR-BI03** ◀◀

Commencing Phase Ia clinical trial in late CY2024

Two Applications



Neuroprotection



Cardioprotection

Three Markets

STROKE

~**US\$52.2 billion** by 2032²

TRAUMATIC BRAIN INJURY

~**US\$5.5 billion** by 2034⁴


MYOCARDIAL INFARCTION

~**US\$3.7 billion** by 2032⁵





Neuroprotection – Stroke and TBI

Serial reconstruction from MRI



DIED BECAME WORSE STAYED THE SAME



Nyrada drug NYR-BI03

An acute 3-day intravenous treatment





Reduce secondary injury resulting from stroke or TBI

- Improve survivability, limit disability
- Improve quality of life

Cardioprotection

Key Preclinical Results:




NYR-BI03 showed strong efficacy limiting cardiovascular damage resulting from myocardial ischemia-reperfusion (IR) injury

- **86%** Cardioprotection
- **43%** increase in left ventricular ejection fraction
- **50%** increase in fractional shortening

Key blood biomarker markers assessed

- **42%** decrease in AST levels
- **45%** decrease in LDH levels
- **32%** decrease in Troponin I

Superior efficacy compared to FDA-approved, Captopril



Indicative Phase I Study Design

OBJECTIVES To assess the safety, tolerability, and pharmacokinetics of NYR-BI03

- DESIGN**
- Randomised, double-blind placebo –controlled, dose escalation design
 - 5 cohorts; 8 participants each cohort; 6:2 active and placebo treatments
 - 3 cohorts will be single ascending doses
 - 2 cohorts will be given continuous infusion doses


PARTICIPANTS

- Male and female healthy volunteers
- 18 – 50 years age



Cohort number	Dose administered
1	Low dose single bolus
2	Medium dose single bolus
3	High dose
4	Low dose continuous infusion (72 hrs)
5	High dose continuous infusion (72 hrs)

- LOCATION & DURATION**
- Study will be conducted at a clinical trial centre in Australia expected to commence 4QCY2024
 - Study duration will vary between 1 – 4 days



*trial design subject to ethics approval

Near Term Catalysts



Late CY2024

NYR-BI03 Clinical Trial
Commencement

Early CY2025

WRAIR TBI study readout

1H CY2025

Progressive updates on
NYR-BI03 Clinical Trial

High Calibre Board with international experience

- › Nyrada operates under the direction of a governing board of international calibre
- › Strong track record in realising the value of biotech companies
- › Experience in dealmaking, US/EU/AU capital markets, and relevant therapeutic area experience



John Moore
Non-Executive Chair



Dr Ian Dixon
Non-Executive Director



Dr Gisela Mautner
Non-Executive Director



Marcus Frampton
Non-Executive Director



Dr Rüdiger Weseloh
Non-Executive Director



Christopher Cox
Non-Executive Director

Management Team with Proven Industry Experience



James Bonnar - CEO

- › Business executive with 25 years of experience in healthcare companies in the UK, China, New Zealand, and Australia
- › Experience in drug manufacture, preclinical development, clinical operations, regulatory affairs, and quality assurance
- › Biotech experience spanning various therapeutic areas including cardiometabolic disease, neurodevelopment disorders, and brain injury



Cameron Jones - CFO

- › Finance executive with experience as CFO and Company Secretary of ASX Listed and VC investee healthcare companies
- › Supported several healthcare companies through IPOs, capital raisings and M&A transactions
- › Managing Director of Bio101, financial services firm
- › Chartered Accountant, Member of the Governance Institute of Australia and Registered Tax Agent



Dr Benny Evison - CSO

- › More than 20 years of experience in the discovery and development of small molecule inhibitors as therapies for various cancers, cardiovascular diseases and neurodegenerative diseases
- › Obtained a PhD at La Trobe University (Melbourne, Australia) in biochemistry and molecular biology, and a postdoctoral fellowship in chemical biology at St Jude Children's Research Hospital, (Memphis TN)

Supported by specialist advisers:

- › **Prof Gary Housley**
Brain injury program
- › **Prof Junichi Nabekura**
Brain injury program
- › **Dr Jim Palmer**
Medicinal Chemist
- › **Dr Mike Bickerdike**
Toxicologist

Large Market Opportunity – Stroke

Globally:

~15 million
people suffer
strokes annually¹

~5 million
left permanently
disabled¹

One approved drug class for stroke suitable for <15% of patients (tPA - tissue plasminogen activator).

Effective treatment will improve patient outcomes and reduce high costs associated with long-term care.

Large and growing treatment market:

Currently
~US\$30.3 billion²

Growing
~7.5% CAGR²

Forecast
**~US\$52.2 billion
by 2030²**



Large Market Opportunity – Traumatic Brain Injury (TBI)

Globally:

~5.5 million
people suffer severe
TBA annually³

~55 million
living with effects of
medically treated TBI³

No current FDA approved treatments

Effective treatment will improve patient outcomes and reduce high costs associated with long-term care of brain injury survivors.

Large and growing treatment market:

Currently
~US\$3.5 billion⁴

Growing
~6.2% CAGR⁴

Forecast
**~US\$5.5 billion by
2030⁴**



Large Market Opportunity – Myocardial Infarction

Globally:

~15-20 million
people suffer heart
attack annually

~15%
mortality within 30
days

No current FDA approved treatments targeting myocardial infarction-reperfusion injury


Effective treatment will improve patient outcomes and reduce high costs associated with long-term care of heart attack survivors.

Large and growing treatment market:

Currently
~US\$1.9 billion⁵

Growing
~6.8% CAGR⁵

Forecast
**~US\$3.7 billion by
2032⁵**



References

- 1 – World Health Organization - <https://www.emro.who.int/health-topics/stroke-cerebrovascular-accident/index.html#:~:text=Annually%2C%2015%20million%20people%20worldwide,cause%20i%20high%20blood%20pressure>
- 2 – Databridge Market Research - <https://www.databridgemarketresearch.com/reports/global-stroke-market> .
- 3 – National Academy of Sciences - <https://nap.nationalacademies.org/catalog/25394/traumatic-brain-injury-a-roadmap-for-accelerating-progress>
- 4 – Databridge Market Research - <https://www.databridgemarketresearch.com/reports/global-traumatic-brain-injuries-treatment-market>
- 5 – Spherical Insights – <https://www.globenewswire.com/en/news-release/2023/05/30/2678779/0/en/Global-Myocardial-Infarction-Market-Size-To-Grow-USD-3-7-Billion-By-2032-CAGR-of-6-8.html>

